Although Musk had previously mentioned using a "small amount once every other week," the billionaire X owner may have been ...

Gilgamesh managed to overcome the issue of functional unblinding in the study, an obstacle experienced by the psychedelic ...

He completed a fellowship in Interventional Neuropsychiatry and Neuromodulation at Massachusetts General Hospital, bringing extensive expertise to the management of treatment-resistant mental health ...

In the new trial, called Study 501, a once-daily oral dose of Caplyta or a matched placebo ... for its nasal spray antidepressant Spravato (esketamine) in 2019 for treatment-resistant depression ...

J&J is already a player in the market for drugs to treat resistant MDD with nasal spray antidepressant Spravato (esketamine), which ... that a once-daily oral dose of Caplyta achieved a ...

Multivariable mixed-effects meta-regressions incorporated drug formulation (racemic (Rac) or esketamine (Esket)) and dose (Low or High) as covariates. Treatment effects were assessed: immediately ...

Gilgamesh Pharmaceuticals, a clinical-stage neuroscience company developing innovative, best-in-class new chemical entities (NCEs) that tran ...

Twenty-one patients (35%) achieved remission with 8 of the 21 patients (38%) needing the 50 mg dose to achieve remission. Median time to remission was 24 weeks and median dose in remission was 30 mg.

Missing a dose of Ozempic may cause several side effects, including constipation, extreme hunger, diarrhea, and nausea, and increase the risk of diabetes complications. Missing an occasional dose ...

Dopamine is an inotropic agent that has vasodilatory effects at low doses. It is a common belief that low-dose dopamine may be helpful in the prevention and treatment of acute renal failure and is ...

People with liver problems: People with mild to moderate liver problems should take about half of the typical venlafaxine dose. People with severe liver disease or cirrhosis may need an even lower ...